Answer to Question 1
ANS: C
The half-life of a low-molecular-weight (LMW) heparin, such as enoxaparin, is up to six times longer than that of unfractionated heparin. Less binding to macrophages and slower clearance by the liver are also factors. Because of enoxaparin's increased bioavailability, the plasma levels of the drug are highly predictable. As a result, it can be given on a fixed schedule with no need for routine monitoring of coagulation.
Enoxaparin is administered subcutaneously (into fatty tissue), and the abdomen is a correct injection site.
LMW heparins, such as enoxaparin, are available only for subcutaneous injection.
Bleeding is the major adverse effect and should be reported if it does not cease.
Answer to Question 2
ANS: C
A daily patch free interval of 10 to 12 hours is recommended. This can be accomplished by applying a new patch each morning, leaving it in place for 12 to14 hours, and then removing it in the evening.
A daily patch free interval of 10 to 12 hours is recommended. This can be accomplished by applying a new patch each morning, leaving it in place for 12 to14 hours, and then removing it in the evening.
An additional patch is never indicated, because hypotension may occur.
Patches should be rotated to different areas to prevent irritation and skin breakdown.